Condition: Healthy · Sponsor: Beijing QL Biopharmaceutical Co.,Ltd
This is a Phase 1, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, tolerability, and pharmacokinetics of ZT003 following subcutaneous administration in healthy adult participants. The study includes both single ascending dose (SAD) and multiple ascending dose (MAD) parts.
This description comes directly from the study's public registry record.
Ruihua Zhao · +86 13581948820 · Ruihua@qlbiopharm.com
Always discuss trial participation with your own doctor first.
| Nucleus Network Brisbane | Brisbane, Queensland, Australia | Recruiting |
| Nucleus Network | Melbourne, Australia | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07184502